# LifeMD, Inc.: Form 10-Q for the period ended Mar 31, 2015

- Company: [LifeMD, Inc.](/companies/lfmd.md) (CIK 948320)
- Form: 10-Q
- Filed: 2015-05-14
- Accepted by EDGAR: May 14, 2015, 16:36 ET
- Period: 2015-03-31
- Accession: 0001213900-15-003705
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/948320/000121390015003705/f10q0315_immudyneinc.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/948320/000121390015003705/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2015-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2015-01-01 to 2015-03-31 | $288.3k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2015-01-01 to 2015-03-31 | $74.2k | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2015-01-01 to 2015-03-31 | $214.1k | us-gaap:GrossProfit |
| Operating income | 3 months, 2015-01-01 to 2015-03-31 | $7.8k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2015-01-01 to 2015-03-31 | $10.5k | us-gaap:InterestExpense |
| Net income | 3 months, 2015-01-01 to 2015-03-31 | $1.7k | us-gaap:NetIncomeLoss |
| Diluted shares (weighted) | 3 months, 2015-01-01 to 2015-03-31 | 31,363,306 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2015-01-01 to 2015-03-31 | −$70.2k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2015-03-31 | $70.1k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2015-03-31 | $187.0k | us-gaap:AssetsCurrent |
| Total assets | at 2015-03-31 | $216.5k | us-gaap:Assets |
| Current liabilities | at 2015-03-31 | $343.4k | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2015-03-31 | $352.3k | us-gaap:Liabilities |
| Shareholders' equity | at 2015-03-31 | −$135.8k | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 20,620 characters.

### Overview

We manufacture, distribute and sell natural immune support products; namely proprietary yeast beta glucans which are natural extracts that have been shown through testing and analysis and scientific research to support the immune system. Yeast beta glucans are classified as generally recognized as safe (“GRAS”) by the Food and Drug Administration (“FDA”). We are and have been a science driven company for more than 25 years. Our products are used in in oral and topical applications. Historically, we have sold our proprietary additives, for both oral and topical use, primarily via business-to-business to large dietary supplement and cosmetic companies. We have also sold our own standalone product lines primarily on a word-of-mouth basis and through our website.

For the first time in our history, we hired a chief marketing officer in 2013, however, we experienced an overall decrease in sales in 2014 due to the lack of execution of plans to generate new business. Late in the second quarter of 2014, the aforementioned chief marketing officer resigned. We hired three senior marketing executives late in the fourth quarter of 2014 (and early in 2015). We have performance based contracts with these executives, allowing us to continue to maintain a relatively low overhead. Our priority is to actively pursue opportunities to market our products and increase sales.

Our plans are to increase sales on our oral and topical-use products for healthcare professionals, distributors and direct-to-consumer sales. We expect that a significant component of our selling, general and administration expenses going forward will continue to consist of marketing and advertising expenses to increase our sales. The primary components of our marketing and advertising expenses may include online sales promotions through our website, trade advertising, direct marketing to nutraceutical companies and industry associations, consumer research and search engine and digital advertising. We expect our selling, general and administrative expenses to increase in absolute dollars as we incur increased costs related to our marketing strategy. These costs, along with the additional costs resulting from our operations as a public reporting company, could continue to adversely impact our future results of operations.

Additional significant factors that we believe will affect our operating results going forward are: (i) protection of our intellectual property rights; (ii) imposition of more stringent government regulations of our products; (iii) lack of adequate capital to effectuate our business plans; and (iv) lack of experienced personnel.

We historically have expended a significant amount of our funds on obtaining and protecting our patents, trade secrets and proprietary products. We rely on the patent and trademark protection laws in the U.S. to protect our intellectual property and maintain our competitive position in the marketplace. For several years, we were involved in complex litigation regarding patents and licenses critical to our products. In 2010, we prevailed on all major legal matters and reached favorable settlements. If additional litigation becomes necessary to protect our intellectual property rights, such litigation may be costly, divert our management’s attention away from our core business and have a negative impact on our operations. Furthermore, there is no guarantee that litigation would result in an outcome favorable to us. In addition, yeast beta glucans are designated as GRAS under current FDA regulations. Future government regulations may prevent or delay the introduction or require the reformulation of our products. Some agencies, such as the FDA, could require us to remove a particular product from the market, delay or prevent the import of raw materials for the manufacture of our products or otherwise disrupt the marketing of our products. Any such government actions could result in additional costs to us, reduce growth prospects, lost sales from products that we are required to remove from the market and potential product liability litigation.

We have limited operating capital and have funded operations in the past through the sales of our products and loans and advances from Mark McLaughlin, our President, and other directors. In addition, in the first quarter of 2014 we received $132,000 from a legal settlement that was used to fund our operations and on September 30, 2014, we borrowed $50,000 pursuant to a short term loan agreement entered into with a private investor for our ongoing working capital needs. This short term loan agreement was paid in full on its maturity on November 14, 2014. In the first quarter of 2015, we entered into another non-dilutive short term loan agreement with an investor for $100,000. With the proceeds from this loan, we plan on our operating business to be able to fund operations through the first half of 2015, however, in the event we require additional operating capital we will have to depend on sources other than operating revenues to meet our operating and capital needs. No assurance can be given that such sources will be available and no assurance can be given that Mr. McLaughlin or other directors who have in the past willingly funded operations will commit to do so in the future, or that we will be successful in our endeavors to raise additional capital. For additional information regarding these and other risks please see our Annual Report on Form 10K for the fiscal year ended December 31, 2014 filed with the SEC on March 30, 2015.

### Results of Operations

### Three Months Ended March 31, 2015, Compared to the Three Months Ended March 30, 2014

The following table sets forth the results of our operations for the periods indicated as a percentage of net sales:

|  | 2015 $% of Sales |  | 2014 $% of Sales |  |
| --- | ---: | ---: | ---: | ---: |
| Sales | 288,277 |  | 192,429 |  |
| Cost of sales | 74,216 | 26% | 49,090 | 26% |
| Gross profit | 214,061 | 74% | 143,339 | 74% |
| Operating expenses | (206,227) | (72)% | (320,977) | (167)% |
| Income (loss) from operations | 7,834 | 3% | (177,638) | (92.5)% |
| Other income (expenses), net | (10,468) | (4)% | 32,399 | 16.8% |
| Income tax benefit | 4,300 | 2% | 4,300 | 2.5% |
| Net income (loss) | 1,666 | 0.1% | (140,939) | (73)% |

Sales for the first quarter of 2015 were $288,277, an increase of 50% from $192,429 for the same period in 2014. Our increase in sales was primarily attributable to the increased demand for our products.

Cost of sales consists primarily of material costs, labor costs and related overhead directly attributable to the production of our products. Total cost of sales increased 51% to $74,216 in the first quarter of 2015 compared to $49,090 for the same period in 2014. Our cost of sales increased primarily due to our overall increase in sales during the quarter.

Gross profit increased 49.3% to $214,061 in the first quarter of 2015 compared to $143,339 for the same period in 2014 as result of our increased sales. Gross profit as a percentage of sales was relatively consistent from year to year as a result of our relatively consistent overhead expenses.

Operating expenses consisted of general and administrative expense, compensation and related expense and professional fees. Operating expenses decreased 36% to $206,227 in the first quarter of 2015 compared to $320,977 for the same period in 2014. General and administration expense decreased by 17% to $85,329 in the first quarter of 2015, compared to $102,363 for the same period in 2014, due to the decrease in the Company’s marketing expenses year over year as a result of the lack of execution of plans to generate new business in the 2014 period. Compensation and related expenses decreased by 48% to $85,390 in the first quarter of 2015, compared to $164,021 for the same period in 2014, due primarily to compensation paid in the 2014 period to our chief marketing officer who has since resigned. Professional fees decreased 35% to $35,508 in the first quarter of 2015, compared to $54,593 for the same period in 2014, as result of additional legal fees incurred in the 2014 period for the pursuit and settlement of litigation which was not similarly incurred in the 2015 period.

Net income for the first quarter of 2015 was $1,666 compared to net loss of $140,939 for the same period in 2014. Net income as a percentage of sales was 0.1% in the first quarter of 2015 compared to net loss as a percentage of sales of 73% for the same period in 2014. Our net income in the first quarter of 2015 as compared to net loss for the same period in 2014 was primarily attributable to our increased sales during the quarter.

### Liquidity and Capital Resources

Our principal demands for liquidity are to increase sales, purchase inventory and for sales distribution and general corporate purposes. We incurred negative cash flows in the 2013 and 2014 fiscal years and had a negative net working capital position at March 31, 2015. As a result, our auditors have raised substantial doubt about our ability to continue as a going concern. We plan on our operating business (in conjunction with our short term non-dilutive borrowing in the first quarter of 2015) being able to fund operations through the first half of 2015. However, if necessary, we may raise additional capital through a private placement of common stock, obtaining debt financing or from advances from our President and/or directors.

In the first quarter of 2014, we received $132,000 pursuant to a legal settlement. On September 30, 2014, we borrowed $50,000 pursuant to a short term loan agreement entered into with a private investor for our ongoing working capital needs which was repaid with cash on hand. During 2014 notes payable due to officer and other related individuals totaling $30,000 were repaid and in the fourth quarter of 2014 we borrowed an additional $17,000 from our President, which was repaid in the first quarter of 2015. Additionally, in the first quarter of 2015 we entered into a short-term non-dilutive loan with an investor for $100,000. At March 31, 2015 we had notes payable outstanding of $91,943.

There can be no assurance that required future financing can be successfully completed on a timely basis, or on terms acceptable to us. Any future issuance of equity securities could cause dilution to our shareholders. Any incurrence of indebtedness would increase our debt service obligations and would cause us to be subject to restrictive operating and financial covenants.

Additionally, at March 31, 2015 and December 31, 2014, one customer accounted for 100% of accounts receivable. We periodically perform a credit analysis and monitor the financial condition of this and other customers and do not foresee any difficulties in collecting our accounts receivable at this time.

We had negative net working capital of $156,437 at March 31, 2015, resulting in a decrease of $178,606 from net working capital of $22,169 at March 31, 2014. The ratio of current assets to current liabilities was .5 to 1 at March 31, 2015.

The following is a summary of cash provided by or used in each of the indicated types of activities during the three months ended March 31, 2015 and 2014:

| Cash provided by (used in): | 2015 | 2014 |
| --- | ---: | ---: |
| Operating activities | $(70,187) | $(6,647) |
| Financing activities | 64,743 | (12,000) |

Net cash flow used by operating activities was $70,187 for the three months ended March 31, 2015, compared to net cash flow used in operating activities of $6,647 for the same period in 2014. The increase in net cash outflow in operating activities was attributable primarily to our receipt of legal settlement proceeds in the first quarter of 2014 which was responsible for the lower level of cash outflows in 2014.

Net cash flows provided by financing activities was $64,743 for the three months ended March 31, 2015, from the $100,000 borrowed under a short-term non-dilutive loan agreement with a private investor offset by certain repayments on notes outstanding, compared to net cash flows used by financing activities of $12,000 for the repayment of a note issued by one of our directors.

### Indebtedness

From time to time, our directors, officers and other related individuals have made short-term advances to us for our operating needs. At March 31, 2015, notes payable due to officers and directors totaled $10,200 and carried interest at 5% per annum. During the three months ended March 31, 2015, a total of $17,000 was repaid. Interest expense on notes payable amounted to $162 for the three months ended March 31, 2015.

In the first quarter of 2015, we borrowed $100,000 pursuant to a short term non-dilutive loan agreement with a private investor. Interest and principal expense on this loan agreement for the three months ended March 31, 2015 amounted to $28,563.

We are subject to a royalty agreement pursuant to which we are required to pay a monthly royalty of 8% on all sales of certain skin care products up to $227,175. At March 31, 2015, we included $151,986 in accounts payable and accrued expenses relating to this royalty agreement, with the remaining commitment under the royalty agreement at approximately $1,000. Our President, Mr. McLaughlin, has a 60% interest in the royalties paid under the agreement and has voluntarily deferred payments due without interest until, from time to time, we have the financial wherewithal to pay such royalties.

### Legal Matters

In October 2013, the Company agreed to a judgment against the estate of a former officer and related individuals in connection with a judgment in favor of the Company rendered in June 2000, finding that defendants in question had failed to use their best efforts in support of the Company in violation of an agreement between the parties. Subsequently, a settlement was reached with these parties in the amount of $386,000. During the year ended December 31, 2013, the Company received net proceeds of $78,000 and the balance, $132,000, net of related legal costs, was received in March 2014.

### Off-Balance Sheet Arrangements

There are no off-balance sheet arrangements between us and any other entity that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to shareholders.

We have not entered into any financial guarantees or other commitments to guarantee the payment obligations of any third parties. We have not entered into any derivative contracts that are indexed to our shares and classified as stockholders’ equity or that are not reflected in our consolidated financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or research and development services with us.

### Critical Accounting Policies

While our significant accounting policies are described more fully in Note 2 to our financial statements, we believe the following accounting policies are the most critical to aid you in fully understanding and evaluating this management discussion and analysis.

#### Basis of Presentation and Use of Estimates

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the U.S., or U.S. GAAP. In preparing financial statements in conformity with U.S. GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant estimates required by management include the valuation of inventory and stockholders’ equity-based transactions. Actual results could differ from those estimates.

#### Inventory

Inventory is valued at the lower of cost or market value with cost determined on a first-in, first-out basis. Management compares the cost of inventory with the net realizable value and an allowance is made for writing down their inventories to market value, if lower.

#### Revenue Recognition

The Company’s policy is to record revenue as earned when a firm commitment, indicating sales quantity and price exists, delivery has taken place and collectability is reasonably assured. The Company generally records sales once the product is shipped to the customer. If applicable, provisions for discounts, returns, allowances, customer rebates and other adjustments are netted with gross sales. The Company accounts for such provisions during the same period in which the related revenues are earned. Customer discounts, returns and rebates have not been significant.

Delivery is considered to have occurred when title and risk of loss have transferred to the customer. Sales to international distributors are recognized in the same manner. If title does not pass until the product reaches the customer’s delivery site, then recognition of revenue is deferred until that time. There are no formal sales incentives offered to any of the Company’s customers. Volume discounts may be offered from time to time to customers purchasing large quantities on a per transaction basis. There are no special post shipment obligations or acceptance provisions that exist with any sales arrangements.

#### Stock-based Compensation

The Company follows the provisions of ASC 718, “Share-Based Payment”. Under this guidance compensation cost generally is recognized at fair value on the date of the grant and amortized over the respective vesting periods. The fair value of options at the date of grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based upon historical exercise patterns and represents the period of time that options granted are expected to be outstanding. The expected volatility is based upon historical volatility of our shares using weekly price observations over an observation period that approximates the expected life of the options. The risk-free rate approximates the U.S. Treasury yield curve rate in effect at the time of grant for periods similar to the expected option life. The estimated forfeiture rate included in the option valuation was zero.

Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense.

### New Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update ("ASU") 2014-09 "Revenue from Contracts with Customers" (Topic 606) ("ASU 2014-09"). ASU 2014-09 is a comprehensive new revenue recognition model requiring a company to recognize revenue to depict the transfer of goods or services to a customer at an amount reflecting the consideration it expects to receive in exchange for those goods or services. In adopting ASU 2014-09, companies may use either a full retrospective or a modified retrospective approach. ASU 2014-09 is effective for the first interim period within annual reporting periods beginning after December 15, 2016, and early adoption is not permitted. The Company will adopt ASU 2014-09 during the first quarter of fiscal 2017. Management is evaluating the provisions of this statement and has not determined what impact the adoption of ASU 2014-09 will have on the Company's financial position or results of operations.

In August 2014, the FASB issued ASU 2014-15, "Presentation of Financial Statements-Going Concern". This ASU is intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. It is effective for annual periods beginning after December 15, 2016, with early adoption permitted. The Company does not expect it to have a material effect on the Company's financial condition, results of operations, and cash flows.

All other accounting standards that have been issued or proposed by the FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption.

## Controls and procedures

As filed, 2,725 characters.

### Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our Principal Executive Officer (“PEO”), who is also our Principal Financial Officer (“PFO”), of the design and effectiveness of our “disclosure controls and procedures” (as defined under Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) as of the end of the period covered by this report. Based on this evaluation, our PEO/PFO concluded that as of the end of the period covered by this report, these disclosure controls and procedures were not effective. The conclusion that our disclosure controls and procedures were not effective was due to the presence of the following material weaknesses in disclosure controls and procedures which are indicative of many small companies with small staff: (i) inadequate segregation of duties and effective risk assessment as the Company had only one officer; (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC Guidelines; and (iii) inadequate security and restricted access to computer systems including insufficient disaster recovery plans; and (iv) no written whistleblower policy. Once sufficient funds are available, our PEO/PFO plans to implement appropriate disclosure controls and procedures to remediate these material weaknesses, including (i) appointing additional qualified personnel to address inadequate segregation of duties and ineffective risk management; (ii) adopt sufficient written policies and procedures for accounting and financial reporting and a whistle blower policy; and (iii) implement sufficient security and restricted access measures regarding our computer systems and implement a disaster recovery plan.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the quarter ended March 31, 2015, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

## Risk factors

As filed, 145 characters.

You should consider carefully the factors discussed in the “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2014.

Filed May 14, 2015.
Source: SEC EDGAR, the filing index for accession 0001213900-15-003705. Last ingested by Listed: Nov 13, 2026, 16:33 ET. No prices; not investment advice.
